Read More

Small-Cap Cancer Focused Theseus Pharmaceuticals Goes Private For Over $3.90/Share In Cash

Theseus Pharmaceuticals Inc (NASDAQ: THRX) on Friday, has entered into a definitive merger agreement whereby Concentra Biosciences LLC will acquire Theseus for a price per share of between $3.90 and $4.05 in cash, consisting of a base cash price of $3.90 per share and an addi

THRX

Read More

Inebriation Remedy And Breakthrough MS Treatment: Meet FSD Pharma

Among a biotech space bursting with innovation, one company stands out as it is developing two assets at once: a ready-for-market drink that can take someone from a drinking state to mental and physical composure in record time and a potential breakthrough therapy for Multiple Sclerosis. Meet FSD Pharma (NASDAQ:

HUGE

Read More

FDA Refuses Neurology-Focused Clene’s Accelerated Approval For Amyotrophic Lateral Sclerosis Treatment, Shares Fall

Clene Inc (NASDAQ: CLNN) provided an amyotrophic lateral sclerosis (ALS) regulatory update from its recent meeting with the FDA to discuss CNM-Au8 for ALS, presenting initial clinical and Neurofilament Light Chain (NfL) biomarker results from the completed 

CLNN